Investors might want to bet on Catalent (CTLT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics ...

Catalent's location in Bloomington has about 2,400 employees, down hundreds of workers in just the past few years. It laid ...

Strengths highlight Catalent's robust biologics segment and expansive global infrastructure. Weaknesses underscore the ...

Catalent Inc (CTLT) stock saw a decline, ending the day at $60.7 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.96. The stock opened at $60.6 and touched a low of $60.49 ...

The contract drug manufacturer was expected to file the report on Aug. 29. The company is awaiting the closing of the $16.5 ...

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.4 which represents a decrease of $-0.32 or -0.53% from the prior close of $60.72. The stock opened at $60.7 and touched a ...

SOMERSET, N.J. — SOMERSET, N.J. — Catalent Inc. (CTLT) on Thursday reported fiscal fourth-quarter net income of $23 million. The Somerset, New Jersey-based company said it had profit of 13 cents per ...

London: Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the fourth quarter of fiscal 2024, ...

The first notable agency action in 2024 is the FTC’s Second Request in Novo Holding’s proposed $16.5 billion acquisition of Catalent, a life sciences contract manufacturer. 1 The agency’s interest in ...

Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies. WHY IT'S ...